Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
omburtamab + diethylenetriaminepentaacetic acid
- Development stage
- Unknown
- Lead developer
- Y-mAbs Therapeutics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intrathecal, Intracerebroventricular
01
Overview
**Omburtamab + diethylenetriaminepentaacetic acid** is an antibody-chelator conjugate consisting of the murine IgG1 monoclonal antibody omburtamab, which binds **B7-H3**, linked to **diethylenetriaminepentaacetic acid** to enable radiolabeling with therapeutic or imaging radionuclides such as iodine-131 or lutetium-177. The construct is being developed primarily for pediatric central nervous system and leptomeningeal malignancies, especially neuroblastoma with CNS/leptomeningeal metastases and recurrent medulloblastoma. Its therapeutic concept is targeted radioimmunotherapy: the antibody directs the conjugate to B7-H3-expressing tumor cells, while the DTPA chelator serves as the metal-binding scaffold for radionuclide delivery. Development has been led by Memorial Sloan Kettering Cancer Center and later Y-mAbs Therapeutics, with intracerebroventricular administration used in key CNS programs.
- Other names
- omburtamab + diethylenetriaminepentaacetic acidomburtamab-DTPADTPA-omburtamab
02
Targets
B7-H3
Beyond the preview
Go deeper on omburtamab + diethylenetriaminepentaacetic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on omburtamab + diethylenetriaminepentaacetic acid.